脑出血后预防性抗癫痫药物使用的差异及其混杂因素
研究分析多中心电子健康记录(2006-2012年,3422例)和单中心前瞻性队列(2007-2015年,450例)中脑出血患者预防性使用左乙拉西坦的种族差异。多中心数据显示白人使用左乙拉西坦的比值比约为黑人的1.71倍,但单中心更完整数据表明该差异被高血压和血肿位置等临床因素混杂。
要点
- 多中心电子健康记录显示脑出血后左乙拉西坦使用存在种族差异。
- 单中心前瞻性队列中该差异被高血压和血肿位置混杂。
- 仅血肿位置与左乙拉西坦使用独立相关。
核心结论
- 多中心电子健康记录显示脑出血后预防性抗癫痫药物使用存在明显的种族差异,但单中心更完整队列发现该差异被高血压和血肿位置等临床因素混杂。
研究设计与样本
- 多中心队列:回顾HealthLNK电子健康记录库2006-2012年4中心3422例脑出血患者,同时进行前瞻性数据记录。
- 单中心队列:2007-2015年前瞻性编码450例脑出血患者。
主要发现
- 多中心队列中左乙拉西坦使用因种族/民族而异(P=0.0000008),白人使用左乙拉西坦的比值比为1.71(95%CI 1.43-2.05,P<0.0001)。
- 单中心队列中血肿位置、年龄较大、意识抑制、血肿体积较大、无酒精滥用及种族/民族与左乙拉西坦使用相关(P≤0.04)。
- 单中心队列中白人使用左乙拉西坦的比值比为1.9(95%CI 1.25-2.89,P=0.002),但该关联被高血压病史、入院时较高血压及深部血肿位置混杂。
- 单中心队列中仅血肿位置与左乙拉西坦使用独立相关(P<0.00001),其他变量包括种族/民族均不显著。
临床怎么用
- 解读电子健康记录中的差异时需警惕未测量的临床因素混杂,需结合详细临床数据验证。
局限性
- 电子健康记录可能缺乏详细临床数据,导致发现的差异可能被混杂。
- 单中心队列样本量较小(n=450),可能影响统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We investigated potential disparities in the use of prophylactic seizure medications in patients with intracerebral hemorrhage. METHODS: Review of multicenter electronic health record (EHR) data with simultaneous prospective data recording. EHR data were retrieved from HealthLNK, a multicenter EHR repository in Chicago, Illinois, from 2006 to 2012 (multicenter cohort). Additional data were prospectively coded (single-center cohort) from 2007 through 2015. RESULTS: The multicenter cohort comprised 3422 patients from 4 HealthLNK centers. Use of levetiracetam varied by race/ethnicity (P=0.0000008), with whites nearly twice as likely as blacks to be administered levetiracetam (odds ratio: 1.71; 95% confidence interval, 1.43-2.05; P<0.0001). In the single-center cohort (n=450), hematoma location, older age, depressed consciousness, larger hematoma volume, no alcohol abuse, and race/ethnicity were associated with levetiracetam administration (P≤0.04). Whites were nearly twice as likely as blacks to receive levetiracetam (odds ratio: 1.9; 95% confidence interval, 1.25-2.89; P=0.002); however, the association was confounded by history of hypertension, higher blood pressure on admission, and deep hematoma location. Only hematoma location was independently associated with levetiracetam administration (P<0.00001), rendering other variables, including race/ethnicity, nonsignificant. CONCLUSIONS: Although multicenter EHR data showed apparent racial/ethnic disparities in the use of prophylactic seizure medications, a more complete single-center cohort found the apparent disparity to be confounded by the clinical factors of hypertension and hematoma location. Disparities in care after intracerebral hemorrhage are common; however, administrative data may lead to the discovery of disparities that are confounded by detailed clinical data not readily available in EHRs.
引用
- Naidech AM, Toledo P, Prabhakaran S, et al. Disparities in the Use of Seizure Medications After Intracerebral Hemorrhage. Stroke. 2017. PMID: 28104834. doi:10.1161/STROKEAHA.116.015779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。